Global Lactose Intolerance Treatment Market is expected to register a CAGR of 5.90% during the assessment period of 2023 to 2030 to reach USD 26.12 Billion by 2030.
India's leading food and milk firm, Drupe Food India, launched Lactose-Free Vegan Milk India in March 2024. People with lactose intolerance benefit from taking lactose-free milk and its products. This condition is common, especially among adults. The body produces an enzyme called lactase that helps it digest lactose properly. In people suffering from this condition, the production of adequate amounts of lactase is stopped by their bodies, thus causing them to experience symptoms such as bloating, cramps, diarrhea, and nausea.
Founder and COO of Drupe Food India discussed the topic by saying, “Drupe is the first natural real almond milk made at a plant in bottles without preservatives, sugar or additives or any artificial flavor substance.” According to these rules, the nutritive content of a meal may be degraded by cooking methods (such as applying sugar) but make it taste better at 50%.
In February 2024, Nestlé SA, a Swiss multinational company, unveiled its initial precision fermentation dairy protein powder known as Better Whey, which does not have animals or lactose and is a whey isolate product under Orgain brand (it had acquired a majority stake in early 2022 for expanding its presence in functional nutrition market). Customers can buy Orgain’s Better Whey via the company’s website. There will also be a small pilot test in-store nationwide across the United States; however, no further details are available yet, according to a Green Queen interview with Nestlé representative. It costs $29.99 per 13.3-ounce tub ($2.3 per ounce). The plant whey-based variety of the brand, which offers similar amount of protein per serving goes for around $1.2 per oz, whereas the second one made from fermented whey could be almost double at approximately $2 per ounce.
In November 2022, Nestlé’s Nescafé Dolce Gusto launched its “Neo,” a next-generation coffee machines and pods. Neo is an exceptional blend of home-based experience in coffeehouses through the highest quality blends that combine both up to date technology as well as sustainability.
In October 2022, Nestle had pronounced their intentions to buy Starbucks’ Seattle's Best Coffee brand. This acquisition will facilitate profitable growth in coffee business by Nestle and strengthen Global Coffee Alliance allowing them both to focus on their areas of specialization.
Lactose intolerance is a medical condition identified by lactase (lactose digesting enzyme) deficiency within the patient’s body. As a result, lactose remains intact and unabsorbed producing various ill-effects such as flatulence, bloating, and abdominal pains. Four types of lactose intolerances are identified, namely, primary lactase deficiency, secondary lactase deficiency, congenital lactase deficiency, and developmental lactase deficiency. Secondary lactase deficiency mainly occurs due to irritable bowel syndrome (IBS), gastroenteritis, Crohn's disease, ulcerative colitis, celiac disease, chemotherapy, and antibiotics. As per the study by the Journal of Health, Population, and Nutrition in 2017, the prevalence of lactose intolerance was significantly higher in IBS-D patients compared to healthy individuals. In this study, some eligible IBS-D patients and healthy individuals were enrolled. In the enrolled individuals, lactose malabsorption was diagnosed by a lactose hydrogen breath test (HBT), and lactose intolerance-related symptoms were monitored for eight hours following lactose administration. It was found that the prevalence of lactose malabsorption was 72% in IBS patients and 60% in healthy individuals.
A study published in the Advances in Clinical and Experimental Medicine in 2015 also showed that the incidence rate of lactose malabsorption with lactose intolerance was 27.16% in pediatric patients with gastrointestinal diseases. Moreover, the highest occurrence was 47.83% in IBS, and the lowest was 15.78% of ulcer disease. IBS represents a significant burden on the US and globally, with an estimated prevalence rate of 14%. From all the information, it is observed that the escalating cases of IBS and other gastrointestinal disorders would boost the US lactose intolerance treatment market
Global Lactose Intolerance Treatment Market is segmented into Type, Treatment, Form, and End User.
Global Lactose Intolerance Treatment Market based on the type has been segmented into primary lactose intolerance, secondary lactose intolerance, congenital lactose intolerance. Primary lactose intolerance dominated the market in 2022. Primary lactose intolerance has a high prevalence rate as compared to others.
The global lactose intolerance treatment market, by treatment, has been segmented into food supplements, enzyme lactase supplements, probiotics. The food supplements segment held the largest market share in 2022. The growing adoption of Lactose-free products is fueling the market growth of this segment.
Based on form, the market has been segmented into powder, liquid, tablet. The powder segment dominated the market in 2022.
The global lactose intolerance treatment market, by end user, has been segmented into homecare, hospitals and clinics, and others. The homecare held the largest share with a CAGR of 6.04%.
Global Lactose Intolerance Treatment Market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
The Americas has been segmented into North America and Latin America, with the North America market further divided into the US and Canada. The Americas spearheaded the market in 2022 and is likely to continue to command during the assessment period. This is attributed to the rising incidence of lactose intolerance and product innovation.
The European lactose intolerance treatment market has been divided into Western Europe and Eastern Europe. The Western Europe lactose intolerance treatment market has further been classified into Germany, France, the UK, Italy, Spain, and the Rest of Western Europe. Europe would follow the Americas during the forecast period owing to the presence of favorable government initiatives, research and development activities, and business expansions by major players.
The lactose intolerance treatment market in Asia-Pacific has been segmented into China, India, Japan, South Korea, Australia, and the Rest of Asia-Pacific. Asia-Pacific is expected to exhibit the highest market growth potential during the forecast period due to increasing healthcare expenditure, distribution of chilled dairy products in China, India, and Australia, and increasing population suffering from lactose intolerance.
The Middle East & Africa lactose intolerance treatment market is segmented into the Middle East and Africa. The Middle East and Africa are highly obsolescence with per capita spend on dairy at just USD 25 per head, the lowest in the world. The underdeveloped infrastructural chain of the region makes it very difficult for the manufacturers to reach their consumers. However, if the affordability rate improves, the growth of the market would be even more dynamic.
The Prominent Players in the Global Lactose Intolerance Treatment Market are:
Some of the key strategies adopted by players operating in the global lactose intolerance treatment market were joint ventures, FDA approvals, acquisitions, expansions, and collaborations, among others.
Available Additional Customizations
Intended Audience
| Report Attribute/Metric | Details |
| Market Size | 26.12 Billion |
| CAGR | 5.90% |
| Base Year | 2022 |
| Forecast Period | 2023 -2030 |
| Historical Data | 2021 |
| Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Type, Treatment, Form, and End User |
| Geographies Covered | North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
| Key Vendors | Abbott (US)., Nestlé (Switzerland), Cargill, Incorporated (US), Dean Foods (US), and Johnson & Johnson Services, Inc. (US) |
| Key Market Opportunities | Infrastructural chain |
| Key Market Drivers | Growing prevalence of lactose intolerance |
Lactose Intolerance Treatment Market Highlights:
Frequently Asked Questions (FAQ) :
lactose intolerance treatment market is expected to be valued at more than USD 26.12 billion by 2030.
The global market is expected to exhibit a strong 5.90% CAGR over the forecast period from 2023 to 2030.
The growing prevalence of lactose intolerance is the major driver for the market.
Europe held a dominant 42% share in the global lactose intolerance treatment market in 2018.
Leading players in the market include Abbott, Nestle, and Cargill Inc., among others.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
